Julie Fox

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

53h-index15.5kcitations391works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(133), HIV Research and Treatment(111), HIV/AIDS drug development and treatment(80), HIV-related health complications and treatments(48), HIV, Drug Use, Sexual Risk(44)

Publications340 total

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases·2025Open Access
What does a trans positive approach in schools look like to LGBTQ + young people?
Journal of Youth Studies·2025Open Access
Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)
Trials·2025Open Access
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial
2025· 2 citedOpen Access
P030 Consequences of low sleep regularity in athletes: a scoping review
SLEEP Advances·2025Open Access
QB RHYMES WITH PASSION: A CELEBRATION OF 25 YEARS OF QUATUOR BOZZINI
Tempo·2025
Sexual risk and HIV prevention choices among men who are mobile for work: Results from a rapid ethnographic assessment for the Mobile Men trial in South Africa and Uganda
PLOS Global Public Health·2025Open Access
Understanding sexual violence: Perspectives from an adolescent HIV prevention study
Journal of Public Health in Africa·2025Open Access
Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in Sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)
2025Open Access
Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm
HIV Research & Clinical Practice·2025· 1 citedOpen Access
Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone
Journal of the International AIDS Society·2025· 2 citedOpen Access
HIV Post Exposure Prophylaxis: prospects, opportunities and challenges
Journal of the International AIDS Society·2025Open Access
694 Clinical Implementation and Dosimetric Analysis of Cone Beam CT Guided Online Adaptive Bladder Radiotherapy
Radiotherapy and Oncology·2025
3407 Feasibility of daily CBCT guided online adaptive treatment for all head and neck tumours
Radiotherapy and Oncology·2025
Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease
European Urology·2025· 5 citedOpen Access
The impact of the healing together programme for children and young people affected by domestic abuse
Children and Youth Services Review·2025Open Access
Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United Kingdom
International Journal of STD & AIDS·2025· 1 cited
Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK–Uganda Comparison
Vaccines·2025· 2 citedOpen Access
Mapping Vaccination Mindsets among UK Residents of Black Ethnicities with HIV: Lessons from COVID-19
AIDS and Behavior·2025· 1 citedOpen Access
Use of doravirine-based regimens in clinical practice in Europe
AIDS·2025
page 1 of 17Next →

Frequent Co-authors

Sarah Fidler(21), John Frater(10), Paul Klenerman(8), Jonathan Weber(8), David Dunn(6), Amanda Clarke(6), Margaret Johnson(6), Nneka Nwokolo(6), Matthew Pace(6), Helen Brown(6), Nicola Robinson(6), Christoph Stephan(6), Mark Gompels(5), Rodney E. Phillips(5), Richard Gilson(4), Iain Reeves(4), Gabriel Schembri(4), Nicola Mackie(4), Stephen Taylor(4), Martin Fisher(4)